Clinical Trials Browser

Interventional × Ustekinumab × Tumor-Agnostic × Clear all

NCT06807593 2026-03-05

Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients

Phase 2 Recruiting

Neoplasms